Apixaban Dose for DVT Prophylaxis in Spinal Cord Injury
Apixaban is NOT the recommended first-line agent for DVT prophylaxis in acute spinal cord injury (SCI). Low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) remain the standard pharmacologic prophylaxis for this high-risk population.
Primary Recommendation: LMWH or UFH
For patients with acute SCI requiring DVT prophylaxis, use LMWH 30 mg subcutaneously every 12 hours (or UFH 5000 units every 8 hours if renal failure is present), initiated as soon as hemostasis is achieved and bleeding risk decreases 1. Acute spinal cord injury within 1 month carries 5 points on the Caprini score, placing these patients in the high-risk category for VTE 1.
Key Clinical Considerations:
- Timing of initiation: Start pharmacologic prophylaxis once hemostasis is assured, typically 24-72 hours after injury if there is evidence of perispinal hematoma 2
- Combination therapy: Mechanical prophylaxis (intermittent pneumatic compression) should be used in addition to pharmacologic prophylaxis 1
- Duration: Continue prophylaxis throughout the acute phase and rehabilitation period 2
- Spinal hematoma risk: VTE pharmacological prophylaxis does not increase the rate of spinal hematoma in spinal injury 3
If Apixaban Must Be Used
While apixaban lacks FDA approval and guideline support for DVT prophylaxis in acute SCI specifically, if apixaban is considered after clinical stabilization as an alternative to heparin (for patient compliance reasons), the prophylactic dose would be 2.5 mg orally twice daily 4. This is the FDA-approved dose for DVT prophylaxis following orthopedic surgery (hip or knee replacement) 4.
However, this approach has significant limitations:
- No evidence base: There are no studies validating apixaban for acute SCI prophylaxis
- Delayed initiation: DOACs may only be considered "after clinical stabilization" 3, not in the acute phase
- Guideline preference: Recent 2024 trauma guidelines explicitly state DOACs "may be considered as an alternative to heparin...after clinical stabilisation" 3, indicating they are not first-line
Critical Pitfalls to Avoid
- Do NOT use apixaban in the acute phase (first 24-72 hours) when bleeding risk assessment is ongoing
- Do NOT use apixaban if neuraxial anesthesia or spinal procedures are planned - the FDA label carries a black box warning about spinal/epidural hematoma risk 4
- Do NOT substitute apixaban for LMWH without strong justification - LMWH has superior evidence in trauma populations 5
- Do NOT use treatment doses (10 mg twice daily) for prophylaxis - this is a common error
Evidence Quality Assessment
The evidence supporting LMWH/UFH over apixaban in SCI is based on:
- Multiple guidelines consistently recommending heparin-based prophylaxis 1, 3
- Meta-analysis showing LMWH superiority in spine trauma (OR 0.78 for DVT, P=0.0050) 5
- Absence of any trials evaluating apixaban specifically in SCI populations
- FDA labeling that does not include SCI as an approved indication 4
The standard of care remains LMWH 30 mg every 12 hours, with dose adjustment based on anti-Xa levels and weight as warranted 3. Apixaban should only be considered as a second-line option after the acute period for long-term prophylaxis when patient compliance with injectable agents is problematic.